Experimental amounts
MOTS-c peptide dosage in animal experiments
The amounts are attached to particular experiments. The human pharmacokinetic record—the account of where a substance goes and how fast it clears—is still missing.
MOTS-c dosage: the published mouse amounts
The published MOTS-c peptide amounts vary with the experiment. In the 2015 metabolic experiments, chronic treatment used about 0.5 mg/kg/day by intraperitoneal injection for about 8 weeks; the acute regimen used 5 mg/kg/day for 7 days. “Per kilogram” adjusts the amount to the animal’s body weight.
The 2021 physical-capacity experiments used 15 mg/kg/day or 15 mg/kg three times weekly, also by intraperitoneal injection. The review covering the bone experiments describes 5 mg/kg/day for 12 weeks in mice.
These are records of what researchers gave animals. The collection contains no established human amount, frequency or treatment duration. Converting the figures by body weight alone would leave absorption, clearance and safety unanswered.
MOTS-c injection routes studied
Intraperitoneal administration places a substance in the abdominal cavity around the organs. It was the route in the founding metabolic study and the mouse performance experiments. The wider research record also includes subcutaneous administration and cells exposed to MOTS-c in culture, as covered by the MOTS-c review.
The route is an experimental condition worth preserving. I distrust a dosage summary that drops it: the point of entry affects the question an experiment can answer about exposure. None of the animal routes supplies an approved human injection method.
MOTS-c half-life
A half-life is the time it takes for a measured amount to fall by half. The available research context supplies no validated human pharmacokinetic half-life, bioavailability or dose-response for MOTS-c. A precise time repeated online would need evidence beyond these sources.
Researchers expect the native peptide to be short-lived in circulation, and animal experiments have used repeated administration. Neither observation supplies a measured human half-life. The literature also discusses a cell-penetrating analogue, a modified form intended to improve delivery. Its findings cannot simply fill the blank for native MOTS-c.
I rank the missing human exposure measurements among the most consequential blanks in this inventory. They would help explain what a future human safety study was actually testing.
MOTS-c side effects and formulation gaps
The reviewed research provides no established clinical side-effect profile from completed human safety trials. Liver effects, interactions with medicines and longer-term harms remain unresolved in people.
Research powders can vary in identity, purity and sterility, and no standardized human formulation is established. Handling details in experimental reports therefore provide no validated preparation or storage procedure for personal use.
I cannot rank an unknown human risk as mild simply because the animal findings look encouraging. The FAQ covers the recurring questions about experiences and timing; the FDA page separates formulation questions from the dated legal record.